title: Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats.
abstract: Although insulin resistance (IR) is a key factor in the pathogenesis of type 2 diabetes (T2D), the precise role of insulin in the development of IR remains unclear. Therefore, we investigated whether chronic basal insulin infusion is causative in the development of glucose intolerance.
  
  
  
  Normoglycemic lean rats surgically instrumented with i.v. catheters were infused with insulin (3mU/kg/min) or physiological saline for 6weeks. At infusion-end, plasma insulin levels along with glucose tolerance were assessed.
  
  
  
  Six weeks of insulin infusion induced glucose intolerance and impaired insulin response in healthy rats. Interestingly, the effects of chronic insulin infusion were completely normalized following 24h withdrawal of exogenous insulin and plasma insulin response to glucose challenge was enhanced, suggesting improved insulin secretory capacity. As a result of this finding, we assessed whether the effects of insulin therapy followed by a washout could ameliorate established glucose intolerance in obese rats. Obese rats were similarly instrumented and infused with insulin or physiological saline for 7days followed by 24h washout. Seven day-insulin therapy in obese rats significantly improved glucose tolerance, which was attributed to improved insulin secretory capacity and improved insulin signaling in liver and skeletal muscle.
  
  
  
  Moderate infusion of insulin alone is sufficient to cause glucose intolerance and impair endogenous insulin secretory capacity, whereas short-term, intensive insulin therapy followed by insulin removal effectively improves glucose tolerance, insulin response and peripheral insulin sensitivity in obese rats.
  
  
  
  New insight into the link between insulin and glucose intolerance may optimize T2D management.
authors.affiliation: Department of Pediatrics, Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Shereen M
authors.initials: SM
authors.lastname: Hamza
authors.affiliation: Department of Pediatrics, Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Miranda M
authors.initials: MM
authors.lastname: Sung
authors.affiliation: Department of Pediatrics, Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.affiliation: Department of Pediatrics, Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Carrie-Lynn M
authors.initials: CM
authors.lastname: Soltys
authors.affiliation: Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
authors.forename: Nancy P
authors.initials: NP
authors.lastname: Smith
authors.affiliation: Department of Pharmacology, University of Alberta, Edmonton, AB, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
authors.forename: Patrick E
authors.initials: PE
authors.lastname: MacDonald
authors.affiliation: Department of Pharmacology, University of Alberta, Edmonton, AB, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Light
authors.affiliation: Department of Pediatrics, Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada; Department of Pharmacology, University of Alberta, Edmonton, AB, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. Electronic address: jason.dyck@ualberta.ca.
authors.forename: Jason R B
authors.initials: JR
authors.lastname: Dyck
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D018149:Glucose Intolerance / Q000097:blood; D005951:Glucose Tolerance Test / Q000379:methods; D007328:Insulin / Q000008:administration & dosage*; D007333:Insulin Resistance / Q000502:physiology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D009765:Obesity / Q000097:blood* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013851:Thinness / Q000097:blood* / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D005947:Glucose
keywords: Glucose intolerance; Insulin infusion; Liver; Skeletal muscle; Type 2 diabetes; p-Akt